First- and second-trimester Down syndrome screening markers in pregnancies achieved through assisted reproductive technologies (ART): a FASTER trial study

2006 ◽  
Vol 26 (8) ◽  
pp. 672-678 ◽  
Author(s):  
G. Lambert-Messerlian ◽  
L. Dugoff ◽  
J. Vidaver ◽  
J. A. Canick ◽  
F. D. Malone ◽  
...  
Keyword(s):  
Down Syndrome ◽  
Assisted Reproductive Technologies ◽  
Reproductive Technologies ◽  
Second Trimester ◽  
Down Syndrome Screening

scholarly journals Hyperglycosylated Human Chorionic Gonadotropin (Invasive Trophoblast Antigen) Immunoassay: A New Basis for Gestational Down Syndrome Screening

1999 ◽  
Vol 45 (12) ◽  
pp. 2109-2119 ◽  
Author(s):  
Laurence A Cole ◽  
Shohreh Shahabi ◽  
Utku A Oz ◽  
Ray O Bahado-Singh ◽  
Maurice J Mahoney
Keyword(s):  
Down Syndrome ◽  
False Positive ◽  
False Positive Rate ◽  
Normal Karyotype ◽  
Screen Test ◽  
Β Subunit ◽  
Second Trimester ◽  
Marker Test ◽  
Positive Rate ◽  
Down Syndrome Screening

Abstract Background: Serum human chorionic gonadotropin (hCG) and hCG free β-subunit tests are used in combination with unconjugated estriol and α-fetoprotein in the triple screen test, and with the addition of inhibin-A in the quadruple marker test for detecting Down syndrome in the second trimester of pregnancy. These tests have a limited detection rate for Down syndrome: ∼40% for hCG or free β-subunit alone, ∼60% for the triple screen test, and ∼70% for the quadruple marker test, all at 5%, or a relatively high, false-positive rate. New tests are needed with higher detection and lower false rates. Hyperglycosylated hCG (also known as invasive trophoblast antigen or ITA) is a new test. It specifically detects a unique oligosaccharide variant of hCG associated with Down syndrome pregnancies. We evaluated this new Down syndrome-directed test in prenatal diagnosis. Methods: Hyperglycosylated hCG was measured in urine samples from women undergoing amniocentesis for advanced maternal age concerns at 14–22 weeks of gestation, 1448 with normal karyotype and 39 with Down syndrome fetuses. Results: The median hyperglycosylated hCG value was 9.5-fold higher in Down syndrome cases (9.5 multiples of the normal karyotype median). The single test detected 80% of Down syndrome cases at a 5% false-positive rate. Urine hyperglycosylated hCG was combined with urine β-core fragment (urine breakdown product of serum hCG free β-subunit), serum α-fetoprotein, and maternal age-related risk. This urine-serum combination detected 96% of Down syndrome cases at a 5% false-positive rate, 94% of cases at a 3% false-positive rate, and 71% of cases at a 1% false-positive rate. These detection rates exceed those of any previously reported combination of biochemical markers. Conclusions: Hyperglycosylated hCG is a new base marker for Down syndrome screening in the second trimester of pregnancy. The measurement of hyperglycosylated hCG can fundamentally improve the performance of Down syndrome screening protocols.

Spontaneous heterotopic triplet pregnancy with intrauterine monochorionic-monoamnionic twins

2016 ◽  
Vol 5 (2) ◽  
pp. 117-119
Author(s):  
Alexander Kotlyar ◽  
Jennifer Eaton ◽  
Katherine Singh ◽  
Uma Perni
Keyword(s):  
Abdominal Pain ◽  
Assisted Reproductive Technologies ◽  
Reproductive Technologies ◽  
Heterotopic Pregnancy ◽  
Second Trimester ◽  
Triplet Pregnancy ◽  
Intrauterine Pregnancy ◽  
Chorionic Villi ◽  
Prior Use ◽  
Unusual Phenomenon

Abstract Heterotopic pregnancies are an unusual phenomenon, which have recently become more prevalent with assisted reproductive technologies (ART). Triplets that are part of a heterotopic pregnancy are exceedingly rare. Here, we describe a case of a woman who presented at 15+1 weeks of gestational age with a known monochorionic-monoamniotic intrauterine pregnancy with several days of abdominal pain with an otherwise unremarkable gastrointestinal (GI) assessment. Salpingectomy was performed, and pathology revealed chorionic villi within the fallopian tube consistent with a heterotopic triplet pregnancy. This pregnancy was conceived spontaneously. Even without the prior use of ART, physicians need to be aware of the risk of heterotopic pregnancy in a patient with a known twin gestation. In addition, this case highlights how heterotopic triplets can present even within the second trimester.

Combining first and second trimester markers for Down syndrome screening: Think twice

2008 ◽  
Vol 48 (5) ◽  
pp. 492-500 ◽  
Author(s):  
Robert COCCIOLONE ◽  
Kate BRAMELD ◽  
Peter O’LEARY ◽  
Eric HAAN ◽  
Peter MULLER ◽  
...  
Keyword(s):  
Down Syndrome ◽  
Second Trimester ◽  
Down Syndrome Screening

scholarly journals 350: Observed:expected ratios: assessment of nasal bone length for second-trimester Down syndrome screening in a user-friendly fashion

2011 ◽  
Vol 204 (1) ◽  
pp. S143
Author(s):  
Jennifer McNamara ◽  
Harish Sehdev ◽  
Alison Cahill ◽  
Linda Odibo ◽  
George Macones ◽  
...  
Keyword(s):  
Down Syndrome ◽  
Nasal Bone ◽  
Second Trimester ◽  
Bone Length ◽  
Nasal Bone Length ◽  
User Friendly ◽  
Down Syndrome Screening

Down syndrome maternal serum markers in oocyte donation and other assisted reproductive technologies

2017 ◽  
Vol 37 (11) ◽  
pp. 1155-1159 ◽  
Author(s):  
Aurore Bonnin ◽  
Françoise Muller ◽  
Marie-Victoire Senat ◽  
Corinne Sault ◽  
Armelle Galland ◽  
...  
Keyword(s):  
Down Syndrome ◽  
Assisted Reproductive Technologies ◽  
Reproductive Technologies ◽  
Oocyte Donation ◽  
Serum Markers ◽  
Maternal Serum

Comparison of the efficiency of second-trimester nasal bone hypoplasia and increased nuchal fold in Down syndrome screening

2008 ◽  
Vol 199 (3) ◽  
pp. 281.e1-281.e5 ◽  
Author(s):  
Anthony O. Odibo ◽  
Harish M. Sehdev ◽  
Sabrina Gerkowicz ◽  
David M. Stamilio ◽  
George A. Macones
Keyword(s):  
Down Syndrome ◽  
Nasal Bone ◽  
Second Trimester ◽  
Down Syndrome Screening
Sign in / Sign up

Export Citation Format

Share Document